NXL
Nexalin Technology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
NXL Profile
Nexalin Technology, Inc.
A company that develops Nexalin medical device to treat depression, anxiety, insomnia, addiction, and early dementia
Healthcare Equipment and Supplies
10/19/2010
09/16/2022
NASDAQ Stock Exchange
6
12-31
Common stock
1776 Yorktown, Suite 550, Houston, TX 77056
--
Nexalin Technology, Inc., was incorporated as a Nevada corporation on October 19, 2010. On December 1, 2021, the Company became a newly formed Delaware corporation. The company designs and develops innovative neurostimulation products that help combat the ongoing global mental health epidemic in unique and effective ways. The company has developed an easy-to-manage medical device — dubbed "Generation 1" or "Gen 1" — that uses bioelectronic medical technology to treat anxiety and insomnia without the need for medication or psychotherapy. The Company's original Gen-1 device, a cranial electrotherapy stimulation (CES) device that emits waveforms at 4 mAh during treatment, is currently classified as a Class II device by the U.S. Food and Drug Administration (" FDA ").
